Anzeige
Mehr »
Lynx Broker
Login
Donnerstag, 22.08.2019 Börsentäglich über 12.000 News von 607 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

WKN: A0YD8Q ISIN: US58933Y1055 Ticker-Symbol: 6MK 
Tradegate
22.08.19
15:30 Uhr
78,50 Euro
0,00
0,00 %
1-Jahres-Chart
MERCK & CO INC Chart 1 Jahr
5-Tage-Chart
MERCK & CO INC 5-Tage-Chart
RealtimeGeldBriefZeit
78,50
79,00
15:32
78,00
78,50
15:30

Aktuelle News zur MERCK & CO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11:35Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication'1
09:46U.S. Department of Health giving $23 million to Merck to make Ebola vaccine-
09:10HHS pledges $23M for Merck's Ebola vaccine2
Börsennews zur MERCK & CO Aktie und weiteren Hot Stocks erhalten
MiHHS to provide $23 million to Merck for Ebola vaccine production2
MiRa Pharma earns milestone from Merck on start of early-stage study5
FrHow Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals13
FrMerck's Cancer Immunotherapy Keytruda Continues to Aid Growth9
FrLeerink likes Merck in premarket analyst action2
15.08.MacroGenics, Incyte's PD-1 med to face off with Merck's Keytruda in a first for cancer R&D28
15.08.Merck collaborates to examine Keytruda in combination with investigational drug1
15.08.MacroGenics vs Merck: An underdog plans a premier bout with the heavyweight champion of the PD-1 class7
15.08.AZ, Merck's Lynparza scores market-expanding clinical success-
14.08.AstraZeneca, Merck's latest Lynparza combo win could widen its ovarian cancer reach-
14.08.AstraZeneca and Merck's Lynparza shows positive effect in late-stage ovarian cancer study3
14.08.AstraZeneca and Merck ovarian cancer drug meets primary endpoint in clinical trial2
13.08.Dow jumps 69 points on gains for Apple Inc., Merck shares44
12.08.Merck & Co., Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.08.Ebola trial stopped early as Regeneron, Ridgeback therapies cut death risk; Merck inks deal to test Keytruda with Oncologie's antibody4
08.08.Boris Johnson pledges £250M to spur AI adoption in NHS; SQZ scoops CFO Teri Loxam from Merck-
07.08.Merck and AstraZeneca pile on more positive Lynparza data in bid to break into prostate cancer4
Seite:  Weiter >>
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
52,3,2